ESR1 and breast carcinoma: However, the data should be carefully interpreted because the “endocrine‐treated/chemotherapy‐naive” group might represent patients with ER+ luminal breast cancer, while the “endocrine‐naïve/chemotherapy‐treated” group might be patients with ER− or triple‐negative breast cancer (TNBC).